Health-care companies ticked down after a poor showing from one hotly anticipated vaccine candidate.
Moderna shares slid after the biotech company said its respiratory syncytial virus, or RSV, shot showed 50% efficacy in preventing the illness after 18 months.
Merck shares slipped ahead of a Food and Drug Administration ruling on commercialization of patritumab deruxtecan, a proposed antibody-drug combination treatment for lung cancer jointly developed with Japanese drug maker Daiichi Sankyo.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
06-26-24 1749ET